Kabra Drugs
KABRADRUGSLTD NSE
Kabra Drugs
HealthcareNSE: KABRADRUGSLTD BSE: KABRADG Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹47.23 Cr
Volatility
Moderate
P/E Ratio
6.3
EBITDA
₹5.33 Cr
Return on Equity
-4.4%
Debt to Equity
0.03
Book Value
₹12.49
52W High
₹35.52
52W Low
₹15.5
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Company is almost debt free.
- Company has delivered good profit growth of 96.8% CAGR over last 5 years
Weaknesses
2- Company has a low return on equity of 7.79% over last 3 years.
- Company has high debtors of 279 days.
Growth Rate
Revenue Growth
—
Net Income Growth
-551% lower than
3Y
ROE
-93.53% lower than
3Y
ROCE
-93.53% higher than
3Y
EBITDA Margin (Avg.)
-103%
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7.15 | 19.76 | 30.42 | 35.41 | 46.22 |
| Expenses | 0.12 | 0.13 | 0.11 | 0.37 | 0.55 | 0.4 | 0.53 | 0.24 | 7.67 | 17.72 | 27.99 | 34.07 | 43.43 |
| Operating Profit | -0.12 | -0.13 | -0.11 | -0.37 | -0.55 | -0.4 | -0.53 | -0.24 | -0.52 | 2.04 | 2.43 | 1.34 | 2.79 |
| OPM % | — | — | — | — | — | — | — | — | -7.27% | 10.32% | 7.99% | 3.78% | 6.04% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.64 | 0.02 | 0.18 | 0.18 | 0.11 | 0.08 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 | 0.01 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 | 0 | 0.01 | 0.01 | 0.02 | 0.02 |
| PBT | -0.12 | -0.13 | -0.11 | -0.37 | -0.55 | -0.4 | -0.53 | 0.39 | -0.5 | 2.21 | 2.6 | 1.42 | 2.84 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 16.74% | 1.54% | 25.35% | 25.35% |
| Net Profit | -0.12 | -0.13 | -0.11 | -0.37 | -0.55 | -0.4 | -0.54 | 0.39 | -0.5 | 1.84 | 2.57 | 1.06 | 2.12 |
| EPS in Rs | -0.27 | -0.3 | -0.25 | -0.84 | -1.25 | -0.4 | -0.54 | 0.16 | -0.21 | 0.78 | 1.08 | 0.45 | 0.89 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 8 | 10 | 8 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 93 | 132 |
| Expenses | 8 | 9 | 7 | 3 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 87 | 123 |
| Operating Profit | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | -1 | -2 | 5 | 9 |
| OPM % | 6% | 4.7% | 6% | -57% | — | -150% | — | — | -3400% | — | — | 6% | 7% |
| Other Income | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | 0 | 0 | 0 | -2 | 0 | 0 | 0 | 0 | 0 | -1 | -1 | 6 | 9 |
| Tax % | 36% | 40% | 7% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 13% | — |
| Net Profit | 0 | 0 | 0 | -2 | 0 | 0 | 0 | 0 | 0 | -1 | -1 | 5 | 8 |
| EPS in Rs | 0.16 | 0.07 | 0.3 | -5.38 | -0.36 | -0.14 | -0.41 | -0.43 | -0.77 | -1.69 | -0.46 | 2.09 | 3.2 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 24 | 24 |
| Reserves | -2 | -2 | -2 | -4 | -4 | -4 | -5 | -5 | -5 | -3 | 1 | 6 |
| Borrowings | 3 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 0 | 1 |
| Other Liabilities | 3 | 4 | 2 | 1 | 1 | 1 | 1 | 0 | 0 | 2 | 0 | 56 |
| Total Liabilities | 9 | 9 | 6 | 2 | 1 | 1 | 1 | 1 | 1 | 5 | 25 | 86 |
| Fixed Assets | 3 | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 6 | 6 | 4 | 2 | 1 | 1 | 1 | 1 | 1 | 5 | 25 | 85 |
| Total Assets | 9 | 9 | 6 | 2 | 1 | 1 | 1 | 1 | 1 | 5 | 25 | 86 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -5 | -9 |
| Investing | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 |
| Financing | 1 | 0 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 3 | 23 | 0 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 19 | -11 |
| Free Cash Flow | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | -5 | -10 |
| CFO/OP | -38 | 67 | 73 | 10 | 138 | 100 | 167 | 72 | 100 | 28 | 274 | -173 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 198 | 204 | 141 | 254 | -11,406 | — | — | — | — | — | — | 279 |
| Inventory Days | 26 | 16 | 17 | 0 | 0 | — | — | — | — | — | — | 0 |
| Days Payable | 130 | 140 | 97 | — | — | — | — | — | — | — | — | — |
| Cash Conversion Cycle | 94 | 80 | 61 | 254 | -11,406 | — | — | — | — | — | — | 279 |
| Working Capital Days | 86 | 70 | 34 | -28 | -912 | — | — | — | — | — | — | 66 |
| ROCE % | 4% | 4% | 7% | -44% | -19% | -9% | -27% | -29% | -53% | -43% | -8% | 21% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Kabra Drugs insights
60 extracted metrics + investor summaries across FY07–FY26.
Documents
1
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
8 May - Postal ballot seeks renaming to Aanjaay Industries and adding businesses in drones, energy, steel, healthcare, AI. 8 May - Postal ballot seeks renaming to Aanjaay Industries and adding businesses in drones, energy, steel, healthcare, AI.
2
Board Meeting Outcome for Outcome Of Board Meeting Held On 06Th May 2026
6 May - Board approved pharma expansion, defence-AI entry, consultant appointment, and revised postal ballot dates on 06 May 2026. 6 May - Board approved pharma expansion, defence-AI entry, consultant appointment, and revised postal ballot dates on 06 May 2026.
3
Announcement under Regulation 30 (LODR)-Press Release / Media Release
6 May - Board approved phased pharma expansion, AI-defence R&D facility in Chennai, SCOMET license process, and appointed independent consultant. 6 May - Board approved phased pharma expansion, AI-defence R&D facility in Chennai, SCOMET license process, and appointed independent consultant.
4
Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 06Th May 2026
27 Apr - Board meeting on 06 May 2026 to discuss pharma expansion and defense AI opportunities. 27 Apr - Board meeting on 06 May 2026 to discuss pharma expansion and defense AI opportunities.
5
Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 06Th May 2026
12h - Board meeting on 06 May 2026 to discuss pharma expansion and defense AI opportunities. 12h - Board meeting on 06 May 2026 to discuss pharma expansion and defense AI opportunities.
Frequently Asked Questions about Kabra Drugs
What does Kabra Drugs Ltd do?
Incorporated in 1989, Kabra Drugs Ltd deals in pharmaceutical products, biological API’s and biochemicals.[1]
Where is Kabra Drugs Ltd (524322) listed?
Kabra Drugs Ltd trades as KABRADRUGSLTD on the NSE and under code KABRADG on the BSE.
Which sector does Kabra Drugs Ltd belong to?
Kabra Drugs Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Kabra Drugs Ltd?
Kabra Drugs Ltd has a market capitalisation of ₹47.23 Cr, which places it in the Small Cap band.
What is the PE ratio of Kabra Drugs Ltd?
Kabra Drugs Ltd trades at a PE ratio of 6.30, against a book value of ₹12.49 per share.
What is the 52-week high and low of Kabra Drugs Ltd?
Over the last 52 weeks Kabra Drugs Ltd has traded between ₹15.5 and ₹35.52.
What is the Return on Equity (ROE) of Kabra Drugs Ltd?
Kabra Drugs Ltd reported a return on equity of -4.40%. Its debt-to-equity ratio is 0.03.
Company Information
Incorporated in 1989, Kabra Drugs Ltd deals in pharmaceutical products, biological API’s and biochemicals.[1]
Website kabradrugs.com
Face Value ₹ 10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524322.md for Kabra Drugs Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.